Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients

Cancer

Volumn 118, Issue 12, 2012, Pages 3173-3181

  Mullins, C Daniel ^a   Hsiao, Fei Yuan ^a,b   Onukwugha, Eberechukwu ^a   Pandya, Naimish B ^c   Hanna, Nader ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Colon cancer; Comparative effectiveness research; Cost effectiveness; Irinotecan; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

AFRICAN AMERICAN; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COLON SURGERY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ELDERLY CARE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RACE DIFFERENCE; SENSITIVITY ANALYSIS; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 84861886858     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26613     Document Type: Article

References (20)

1. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 2000;321:531-535.
2. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22:3766-3775.
3. Golfinopoulos V, Salanti G, Pavlidis N, et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8:898-911. (Pubitemid 47488054)
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomized trial. Lancet. 2000;355:1041-1047. (Pubitemid 30162806)
5. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947. (Pubitemid 30644117)
6. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multi-center randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147. (Pubitemid 30036347)
7. Tangka FK, Trogdon JG, Richardson LC, et al. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116:3477-3484.
8. Lansdorp-Volgelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101:1412-1422.
9. Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc. 2009;57:1403-1410.
10. Davidoff AJ, Rapp T, Onukwugha E, et al. Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation. Med Care. 2009;47:1229-1236.
11. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-104-117.
12. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415-430. (Pubitemid 34752613)
13. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:106-108. (Pubitemid 41139681)
14. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94:1650-1657. (Pubitemid 29260460)
15. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30. (Pubitemid 41095110)
16. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721-5727.
17. Wong YN, Meropol NJ, Speier W, et al. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009;115:2081-2091.
18. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332-342. (Pubitemid 30479101)
19. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641. (Pubitemid 36898950)
20. Eichler H-G, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-528. (Pubitemid 39390832)